As medical device manufacturers face mounting pressures to reduce environmental risk, improve traceability, and accelerate product development, Americhem is preparing to highlight a suite of new technologies that reflect these industry shifts at Pharmapack (Paris) and MD&M West (Anaheim) in early 2026.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260112893294/en/

Americhem’s laser-marking ready thermoplastics enable permanent, high-contrast part identification directly on molded medical components—ideal for cleanroom environments where labels or inks are not viable. Designed for compliance and traceability, these materials support regulatory and workflow demands in modern device manufacturing.

The company, known for its healthcare-focused polymer compounds and masterbatches, will showcase five key technologies, each designed to respond to the technical and regulatory complexities facing modern medtech—particularly in areas like connected care, self-administered delivery, and robotic-assisted interventions. Among the engineered solutions:

• PFAS-Free Internally Lubricated Compounds: Under the EcoLube™ MD umbrella, Americhem is advancing a portfolio of tribological materials engineered to reduce friction and wear without relying on PFAS additives. Applications include auto-injectors, wearable pumps, and precision robotic tools.
• Laser Marking-Ready Thermoplastics: Materials that enable high-contrast, permanent part identification directly on plastic components—eliminating the need for labels or inks in cleanroom environments.
• High-Performance Transparent Alloys: New polymer blends offering an alternative to incumbent clear materials, with improved sterilization durability and toughness for structural medical components.
• Regulatory-Ready Color Masterbatch: Additions to the ColorRx® line aim to help OEMs navigate color compliance challenges, offering ISO 10993-tested, locked formulations that align with clean compounding and cGMP manufacturing standards.
• nDryve™ Additive for Medical Nonwovens: A PFAS-free, in-melt surface modifier targeting nonwoven applications like surgical gowns and hygiene drapes, developed in response to growing demand for fluorine-free fluid repellency.

Americhem is actively engaging with OEM partners to co-develop and validate them for next-generation device applications. The company reports continued double-digit growth in its healthcare segment, supported by its ISO 13485-certified facilities in the U.S. and Denmark and upcoming expansion into China in 2026.

Americhem will also participate in the SPE Minitec Conference held during MD&M West, joining technical discussions on materials innovation for evolving care models.

“There’s a clear shift happening—material choices are now deeply tied to sustainability goals, regulatory scrutiny, and device functionality,” said Matt Miklos, Vice President of Corporate Strategy and M&A at Americhem. “What we’re bringing to these shows is not a catalog—it’s a pipeline of engineered solutions designed to be customized, scaled, and validated in partnership with OEMs who are navigating that complexity every day.”

Americhem’s approach emphasizes long-term material consistency, global compliance, and early design collaboration—factors increasingly prioritized by engineering and R&D teams charged with building the next wave of medical devices.

For technical inquiries or to request early access to sample materials, visit www.americhem.com/industries/healthcare/.

About Americhem

Americhem is an innovative, technology-driven leader in the global polymer industry. Its foundation is built around delivering Performance, Solutions and Trust through close collaboration with customers. All of the company's products are backed by complete technical support that ensures quality, reliability, and value. Americhem operates 10 manufacturing plants and maintains sales offices throughout the world. Visit www.Americhem.com for more information.

View source version on businesswire.com: https://www.businesswire.com/news/home/20260112893294/en/